icon-folder.gif   Conference Reports for NATAP  
 
  EASL 44th Annual Meeting
April 22-26, 2009
Copenhagen, Denmark
Back grey_arrow_rt.gif
 
 
 
Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil
 
 
  EASL
Reported by Jules Levin
 
T Berg,1 B Moller,1 H Trinh,2 S Chan,3 P Marcellin,4 E Suarez,5 A Snow-Lampart,6 D Oldach,6 J Sorbel,6 K Borroto-Esoda,6 D Frederick,6 and F Rousseau6 1Berlin, Germany; 2San Jose, CA, USA; 3Flushing, NY, USA; 4Clichy, France; 5Sevilla, Spain; 6Gilead Sciences, Inc., Durham, NC, USA
 
AUTHOR CONCLUSIONS
 
Both treatment strategies (TDF monotherapy with option to add FTC as combination FTC/TDF, or initial combination of FTC/TDF) were equivalent through 96 weeks of follow-up in this heavily pretreated, highly viremic population
 
There is a non significant trend favoring combination for antiviral efficacy when considering subjects who added FTC or switched from blinded FTC/TDF to open-label as failures
 
In patients with incomplete viral suppression on ADV majority with prior/current LAM use, the complete viral suppression noted in most patients at Week 48 on TDF or FTC/TDF (81% in both arms) was maintained at Week 96 (89% TDF; 85% FTC/TDF)
 
Virologic response was independent of pre-existing ADV or LAM-associated mutations

Introd-1.gif

TDF-2.gif

Resulte-3.gif

Two-4.gif

versus-5.gif

Visit-6.gif

ITT-7.gif

contd-8.gif

At-9.gif

Lam-10.gif

Reference
 
1. Berg et al, EASL 2008;